Merck's Head-long Leap into Follow-On Biologics
Executive Summary
Merck outlined ambitious and capital-intensive plans for a biosimilars business at its annual investor day in early December. The company aims to leverage its 2006 acquisition of GlycoFi to launch six or more follow-on biologics between 2012 and 2017. The news shifts the Big Pharma in an entirely new direction, one that pharmaceutical companies--with the exception of Novartis AG's Sandoz division--have largely stayed away from.
You may also be interested in...
Believing In Biosimilars: Industry Takes Long View on FDA Pathway
FDA is open for business on biosimilars as it works out the specifics of the new review pathway. But for companies considering an entry into the space, two big questions still remain: Does a profitable market exist, and how conservative will FDA be on those initial approvals? Executives from across the biopharmaceutical industry weigh in during The RPM Report’s FDA/CMS Summit.
Opening A Door To Biosimilars In The US
With the regulatory door ajar, companies across the pharmaceutical industry are vying to dominate the biosimilars space, despite the commercial risks.
Opening A Door To Biosimilars In The US
With the regulatory door ajar, companies across the pharmaceutical industry are vying to dominate the biosimilars space, despite the commercial risks.